Zacks Investment Research Lowers X4 Pharmaceuticals (NASDAQ:XFOR) to Hold

Zacks Investment Research cut shares of X4 Pharmaceuticals (NASDAQ:XFOR) from a buy rating to a hold rating in a research note issued to investors on Saturday morning, Zacks.com reports.

According to Zacks, “X4 Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s product candidates include X4P-001, X4P-002 and X4P-003 which are in clinical stage. X4 Pharmaceuticals Inc., formerly known as Arsanis, Inc., is based in Cambridge, United States. “

Several other analysts have also recently issued reports on XFOR. ValuEngine cut X4 Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, October 30th. Cowen reiterated a buy rating on shares of X4 Pharmaceuticals in a research report on Thursday, October 10th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. The company currently has an average rating of Hold and a consensus target price of $27.00.

Shares of NASDAQ XFOR traded up $0.03 during trading on Friday, reaching $13.44. The company had a trading volume of 16,800 shares, compared to its average volume of 36,046. The business’s 50-day moving average is $12.45. The company has a current ratio of 7.32, a quick ratio of 7.32 and a debt-to-equity ratio of 0.25. X4 Pharmaceuticals has a 12-month low of $6.90 and a 12-month high of $29.46.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Several large investors have recently added to or reduced their stakes in the stock. Strs Ohio boosted its holdings in shares of X4 Pharmaceuticals by 63.2% in the 3rd quarter. Strs Ohio now owns 3,100 shares of the company’s stock worth $39,000 after purchasing an additional 1,200 shares during the period. Orbimed Advisors LLC boosted its holdings in shares of X4 Pharmaceuticals by 200.6% in the 2nd quarter. Orbimed Advisors LLC now owns 936,493 shares of the company’s stock worth $14,047,000 after purchasing an additional 625,000 shares during the period. Susquehanna International Group LLP purchased a new position in shares of X4 Pharmaceuticals in the 2nd quarter worth approximately $178,000. Morgan Stanley boosted its holdings in shares of X4 Pharmaceuticals by 584.0% in the 2nd quarter. Morgan Stanley now owns 3,379 shares of the company’s stock worth $50,000 after purchasing an additional 2,885 shares during the period. Finally, Cormorant Asset Management LP boosted its holdings in shares of X4 Pharmaceuticals by 252.3% in the 2nd quarter. Cormorant Asset Management LP now owns 890,387 shares of the company’s stock worth $13,356,000 after purchasing an additional 637,638 shares during the period. Hedge funds and other institutional investors own 61.11% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonists of chemokine receptor CXCR4, which is in Phase I clinical trial to treat severe congenital neutropenia; Phase I/II clinical trial for the treatment of Waldenström macroglobulinemia; and Phase IIa clinical trial to treat clear cell renal cell carcinoma, as well as that has completed Phase II clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.

Featured Article: Understanding debt-to-equity ratio in fundamental analysis

Get a free copy of the Zacks research report on X4 Pharmaceuticals (XFOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Leave a Reply

Your email address will not be published. Required fields are marked *

*